IBOV 175,710.05 ▼ 0.51% IPC MEX 69,711.87 ▲ 0.35% MERVAL 2,848,945 — — USD/BRL5.33▼ 0.22% USD/MXN18.65▼ 0.13% USD/CLP983.77▼ 0.54% USD/COP3,146▼ 0.10% USD/PEN3.45▲ 0.03% USD/ARS1,538— 0.00% USD/UYU40.21▲ 3.50% USD/PYG5,803▲ 4.05% USD/BOB11.97▲ 4.12% USD/DOP61.23▲ 1.88% USD/CRC451.24▲ 2.31% USD/GTQ7.64▲ 3.15% USD/HNL26.87▲ 3.37% USD/NIO36.62▼ 0.02% USD/VES885.90▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69▲ 2.51% USD/TTD6.71▲ 1.96% EUR/BRL5.93▼ 1.15% BRENT 109.58 ▼ 5.38% WTI 100.12 ▼ 1.61% IRON ORE 161.91 — — COPPER 6.65 ▲ 2.24% GOLD 4,073 ▲ 0.85% SILVER 54.49 ▲ 0.70% SOY 1,250 ▲ 0.70% CORN 450.25 ▼ 1.04% WHEAT 614.75 ▼ 0.20% COFFEE 294.35 ▼ 2.19% SUGAR 19.26 ▲ 0.84% ORANGE JUICE 143.20 ▲ 5.45% COTTON 77.90 ▼ 1.47% COCOA 5,581 ▲ 1.66% BEEF 230.73 ▲ 0.33% CATTLE 346.40 ▼ 1.00% LITHIUM 62.43 ▲ 1.89% PETR4 53.31 ▼ 1.06% VALE3 62.88 ▼ 2.33% ITUB4 41.42 ▼ 0.67% BBDC4 15.69 ▼ 1.63% ABEV3 15.40 ▲ 0.20% BBAS3 17.59 ▲ 0.69% B3SA3 15.27 ▲ 1.33% WEGE3 45.78 ▲ 2.81% PRIO3 69.21 ▼ 2.71% SUZB3 47.14 ▼ 0.55% RENT3 31.14 ▼ 1.67% AZZA3 16.72 ▲ 1.15% CSAN3 2.69 ▼ 2.89% RAIZ4 0.34 — 0.00% PCAR3 2.22 ▼ 3.48% GMAT3 3.74 ▲ 2.19% PSSA3 47.75 ▼ 0.89% CVCB3 0.98 — 0.00% POSI3 3.56 ▼ 0.84% SLCE3 16.97 ▼ 2.75% NATU3 5.68 ▼ 3.89% BRKM5 3.80 ▲ 19.50% RANI3 7.34 ▼ 0.54% CSNA3 4.76 ▼ 4.99% IBOV 175,710.05 ▼ 0.51% IPC MEX 69,711.87 ▲ 0.35% MERVAL 2,848,945 — — USD/BRL 5.34 ▼ 1.32% USD/MXN 18.69 ▲ 0.62% USD/CLP 983.47 ▼ 0.57% USD/COP 3,149 ▲ 3.06% USD/PEN 3.45 ▲ 0.17% USD/ARS 1,537 ▼ 0.28% USD/UYU 40.21 ▲ 3.57% USD/PYG 5,803 ▲ 3.78% USD/BOB 11.97 ▲ 4.93% USD/DOP 60.54 ▲ 1.83% USD/CRC 451.24 ▲ 2.13% USD/GTQ 7.64 ▲ 3.23% USD/HNL 26.87 ▲ 3.37% USD/NIO 36.62 ▲ 2.81% USD/VES 885.08 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.63% USD/TTD 6.71 ▲ 2.07% EUR/BRL 5.95 ▲ 7.53% BRENT 109.58 ▼ 5.38% WTI 100.12 ▼ 1.61% IRON ORE 161.91 — — COPPER 6.65 ▲ 2.24% GOLD 4,073 ▲ 0.85% SILVER 54.49 ▲ 0.70% SOY 1,250 ▲ 0.70% CORN 450.25 ▼ 1.04% WHEAT 614.75 ▼ 0.20% COFFEE 294.35 ▼ 2.19% SUGAR 19.26 ▲ 0.84% ORANGE JUICE 143.20 ▲ 5.45% COTTON 77.90 ▼ 1.47% COCOA 5,581 ▲ 1.66% BEEF 230.73 ▲ 0.33% CATTLE 346.40 ▼ 1.00% LITHIUM 62.43 ▲ 1.89% PETR4 53.31 ▼ 1.06% VALE3 62.88 ▼ 2.33% ITUB4 41.42 ▼ 0.67% BBDC4 15.69 ▼ 1.63% ABEV3 15.40 ▲ 0.20% BBAS3 17.59 ▲ 0.69% B3SA3 15.27 ▲ 1.33% WEGE3 45.78 ▲ 2.81% PRIO3 69.21 ▼ 2.71% SUZB3 47.14 ▼ 0.55% RENT3 31.14 ▼ 1.67% AZZA3 16.72 ▲ 1.15% CSAN3 2.69 ▼ 2.89% RAIZ4 0.34 — 0.00% PCAR3 2.22 ▼ 3.48% GMAT3 3.74 ▲ 2.19% PSSA3 47.75 ▼ 0.89% CVCB3 0.98 — 0.00% POSI3 3.56 ▼ 0.84% SLCE3 16.97 ▼ 2.75% NATU3 5.68 ▼ 3.89% BRKM5 3.80 ▲ 19.50% RANI3 7.34 ▼ 0.54% CSNA3 4.76 ▼ 4.99%
since 2009
Wednesday, October 28, 2026

Namibia Africa

Namibia Court Voids Antibiotic Rejection

By · October 20, 2026 · 4 min read
Tintenpalast, the seat of Namibia's parliament in Windhoek, behind a garden with palm trees
NAMIBIA · HEALTH AND COURTS

Key Facts

—Who Judge Orben Sibeya of Namibia’s High Court ruled in a case brought by Econo Investments (Pty) Ltd against the Namibia Medicines Regulatory Council (NMRC).

—What The court set aside the NMRC’s rejection of 140,000 vials of Ceftriaxone Sodium for Injection BP 1g, an injectable antibiotic.

—When The order is dated Thursday, 15 October 2026, two days after the parties settled on 13 October.

—Buyer The vials were meant for the Central Medical Stores of the Ministry of Health and Social Services, under tender G/DP/1313MS-37/2024.

—Costs The court made no order as to costs.

Namibia’s High Court has set aside the medicines regulator’s rejection of 140,000 vials of an injectable antibiotic meant for the state’s Central Medical Stores. The order, dated 15 October, followed a settlement between the supplier and the regulator.

For US readers, the case shows how legal risk can hold up medicine supply to a small African market. It also matters to exporters, because the vials were bought through a state tender.

Settlement Becomes a Court Order

Judge Orben Sibeya made a settlement agreement of 13 October a binding order of the court, according to Namibian outlet Observer24. Econo Investments (Pty) Ltd had challenged the Namibia Medicines Regulatory Council (NMRC), the national drug regulator, over its rejection of the vials.

The product is Ceftriaxone Sodium for Injection BP 1g, made by NCPC Hebei Huamin Pharmaceutical, a Chinese manufacturer. It was ordered under tender G/DP/1313MS-37/2024 and purchase order 235388.

Christuskirche, the landmark Lutheran church in central Windhoek, Namibia
File photo: the Christuskirche in Windhoek. Foto: Shaundd, CC BY-SA 3.0

A Dispute Over an Earlier Decision

Observer24 reports that Econo’s application dates from 2 April 2025, and that an NMRC appeal committee decided on 6 May 2026. Econo argued that the council had to follow that appeal decision when it later rejected the product.

A pharmacist at the Central Medical Stores wrote on 20 September that “given the current stock-out situation for antibiotic items under this contract, expedited submission is needed,” the report says. We could not independently confirm the stock position.

What the Order Does Not Say

The order sets aside the rejection but, as reported, does not say whether the vials have been imported, paid for or distributed. The settlement terms and the council’s reasons for its decision have not been published.

The court made no order as to costs, and the matter was removed from the roll as finalised. Neither the council nor the Health Ministry has commented in the report we reviewed.

What It Means for US Readers

Exporters and investors in African health supply chains should note that a regulator’s rejection can be reversed through court settlement. Procurement timing in Namibia can therefore move with legal outcomes as well as with tenders.

The case involves a Chinese manufacturer and a state buyer, and no US company is named. Exporters selling into state tenders should plan for such disputes.

What Is Not Known

We have not seen the order or the settlement text, and the story rests on one Namibian news report. The report does not say whether Econo is a Namibian company, and we do not state it.

Whether the product holds a current Namibian registration is not reported. Nor is it clear when the vials will arrive or how the stock-out at the Central Medical Stores will be resolved.

Sources

Observer24

The Big Picture

Africa: The New Scramble — why the world’s powers are competing for the continent

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief

Frequently Asked Questions

What did Namibia’s High Court decide?

Judge Orben Sibeya set aside the medicines regulator’s rejection of 140,000 vials of Ceftriaxone Sodium for Injection BP 1g. The order of 15 October 2026 made a settlement of 13 October binding.

Who were the parties?

Econo Investments (Pty) Ltd was the applicant and the Namibia Medicines Regulatory Council the respondent. The vials were intended for the Ministry of Health’s Central Medical Stores.

Who made the antibiotic?

Observer24 names NCPC Hebei Huamin Pharmaceutical of China as the maker. The product is an injectable antibiotic used in hospitals.

Have the vials been delivered?

The report does not say whether the vials have been imported or distributed. The confirmed outcome is limited to the rejection being set aside.

RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Africa Intelligence

One email, every weekday morning. African markets, politics and business — filed from our newsroom in Rio.

Yesterday’s subject line: “Egypt clears forces for Saudi, Red Sea oil at risk”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.